75 results
6-K
EX-99.1
GLPG
Galapagos NV
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
chronic lymphocytic leukemia (rrCLL) and patients with Richter transformation (RT). Further, previously disclosed safety, efficacy and feasibility data …
Galapagos abstracts
Seven-Day Vein-to-Vein Point-of-Care–Manufactured GLPG5201 Anti-CD19 CAR-T Cells Display Early Phenotype in Relapsed/Refractory Chronic
6-K
EX-99.1
GLPG
Galapagos NV
12 Jun 23
Current report (foreign)
7:32am
2023 congress
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter’s … visit is at Week 14 post CAR-T infusion. Phase 1 patient recruitment is ongoing to establish a recommended dose for Phase 2.
About chronic lymphocytic
6-K
EX-99
GLPG
Galapagos NV
4 Apr 17
Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib
12:00am
can be felt throughout the body, often resulting in chronic dryness of the eyes and mouth. Along with symptoms of extensive dryness, other serious … complications include profound fatigue, chronic pain, major organ involvement, neuropathies and lymphomas. The disease is estimated to affect up to 1
6-K
EX-99.1
GLPG
Galapagos NV
12 Dec 23
Current report (foreign)
6:00am
updates on:
EUPLAGIA-1 study with GLPG5201 (CD19 CAR-T) in relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter … for Immunology, Switzerland, studying B lymphocyte development. Next, he studied the molecular mechanisms of the pathogenesis of chronic
6-K
EX-99.1
GLPG
Galapagos NV
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter … of the study. The dose levels that were evaluated in the Phase 1 part of the study are 35x106 (DL1), and 100x106 (DL2) CAR+ viable T cells.
About chronic
6-K
EX-99.1
lva8gi1
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
6-K
EX-99.1
61clpp35x8ubapl3lh
20 Sep 21
Current report (foreign)
9:26am
6-K
EX-99.1
xgt6u1vfpx6
19 May 21
Current report (foreign)
6:00am
6-K
EX-99.1
hxhc jtyv
2 May 23
Current report (foreign)
4:15pm
6-K
EX-99.1
nsvnf
28 May 21
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
6:00am
6-K
EX-99.2
rck027pcuqh rwi8pna
9 Nov 20
Galapagos reports Q3 2020 results
4:01pm
6-K
EX-99.2
ixdq1s6 ueiap91z
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.1
xr9 g8tdfcazqonci
12 Jul 21
New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress
9:02am
6-K
EX-99.1
cprn7k44dhv yvubncq
2 May 18
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
6:00am
6-K
EX-99.2
kzagay8tz
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
6-K
EX-99.2
wvar7inavk
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.2
8cecwz ccr
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
qlgb wswe9y
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
yoz7gzpd8i 6xxtda9i
14 Nov 22
Current report (foreign)
6:05am
6-K
EX-99.2
1tcze
27 Apr 18
Galapagos reports first quarter 2018 results
12:00am